Eli Lilly (NYSE:LLY) has acquired exclusive rights to Entos Pharmaceuticals’ Fusogenix proteolipid vehicle (PLV) drug-delivery technology for central and peripheral nervous system applications. Indianapolis-based Lilly plans on using the platform to discover and develop nucleic acid products. Entos said Fusogenix brings together the best features of viral and lipid-based delivery approaches while avoiding their respective downsides.…